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BACKGROUND: Molecular diagnosis has been proposed to enhance the intra-operative diagnosis of sentinel lymph node (SLN) invasion
in head and neck squamous cell carcinoma (HNSCC). Although cytokeratin (CK) mRNA quantification with real-time reverse
transcriptase-PCR (QRT–PCR) has produced encouraging results, the more discriminating markers remain to be identified.
METHODS: Pemphigus vulgaris antigen (PVA), squamous cell carcinoma antigen (SCCA), and CK17 mRNA were quantified using
QRT–PCR, and the results were compared with an extensive histopathological examination of the entire SLNs on 78 SLNs
harvested from 22 patients with HNSCC.
RESULTS: SCCA and CK17 quantification showed significantly higher mRNA values for macrometastases (MAs) than for either negative
or isolated tumour cell (ITC) SLNs (Po0.01). Pemphigus vulgaris antigen allowed the discrimination of all MAs and micrometastases
from both negative and ITC SLNs (Po0.001). For the neck staging of patients, considering metastatic vs non-metastatic status,
receiver-operating characteristic curve analysis found areas under the curve of 93.8, 97.9, and 100% for CK17, SCCA, and PVA,
respectively. With PVA, a cutoff value of 562 copies per 100ng of cDNA permitted the correct distinction between patients with
positive as opposed to negative neck nodes in all cases.
CONCLUSION: PVA seems to be a highly promising marker for accurate intra-operative SLN staging in HNSCC by QRT–PCR.
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In cN0 head and neck squamous cell carcinoma (HNSCC), use of
the sentinel lymph node (SLN) technique has proved to be valuable
in selecting pNþ patients for therapeutic neck dissection while
sparing unneeded extended neck surgery for pN0 patients.
However, the main pitfall of this strategy is that histopathological
diagnosis based on serial sections with immunohistochemistry
(SS-IHC) is far too time consuming to be made use of during
surgery in routine practice (van Diest et al, 2001). A delayed pN
diagnosis compels pNþ patients (up to 40% of cases) to undergo
further additional surgery with an increased risk of post-operative
complications and a damaged functional outcome (Kuntz and
Weymuller, 1999; Schiefke et al, 2009). In this context, real-time
reverse transcriptase-PCR (RT–PCR) may be helpful because it is
operator independent and, with some adaptation, can be
automated and rapidly performed (Raja et al, 2002; Hamakawa
et al, 2004). In a previous study, we demonstrated that cytokeratin
(CK)17 mRNA quantification could be evaluated in SLNs by semi-
quantitative RT–PCR and that neck staging could be performed
with relevant sensitivity and specificity when compared with SS-
IHC staging (Garrel et al, 2006). However, minute micrometastases
(MIs) sized o450mm produced signals similar to those of negative
SLN controls and were thus undiagnosed by CK17 mRNA level
quantification, showing the limitation of this mRNA marker for
the detection of metastases in SLNs. Therefore, molecular test
accuracy had to be improved so as to minimise the risk of ‘false-
negative’ cases before proposing an effective clinical intra-
operative application of such an approach. Recently, Pemphigus
vulgaris antigen (PVA) and squamous cell carcinoma antigen
(SCCA) have been highlighted as potential tumour-specific mRNA
markers for the molecular staging of cervical lymph nodes in
HNSCC (Ferris et al, 2005). However, to our knowledge, the
reliability and accuracy of these markers has not been evaluated
elsewhere for the molecular diagnosis of occult SLN metastases.
The aims of this study were (1) to develop sensitive and
reproducible quantitative RT–PCR (QRT–PCR) assays for PVA,
SCCA, and CK17 mRNAs for detecting and quantifying metastases
in SLNs of HNSCC; (2) to investigate whether macrometastates
(MAs) and MIs, including those sized o450mm, can be
distinguished from isolated tumour cells (ITCs) and negative
nodes using these assays; and (3) to identify the most accurate
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smarker for molecular analysis of SLNs, compared with an
extensive histopathological examination of serial sections.
MATERIALS AND METHODS
Demographic populations
Between March 2006 and December 2008, every patient seen at the
Head and Neck department of the Montpellier Teaching Hospital
with an untreated oral or oropharyngeal squamous cell carcinoma
(cN0M0) was asked for their consent to be a participant in this
study. The study received ethical approval from the clinical
research board of the hospital. A total of 22 consecutive patients
were included and none refused to participate. The clinical,
demographic, and histopathological characteristics of the popula-
tion are reported in Table 1. Inclusion criteria were the same as
those described in a previous study (Garrel et al, 2005).
SLN detection
Sentinel lymph nodes were detected using a g-probe (X-PROBE
Clerad-ARIES, Chatillon, France) after a peri-tumoural radiotracer
injection (Nanocis, CIS BIO International, Saclay, France) and
lymphoscintigraphy was performed on the day of surgery, as
previously described (Garrel et al, 2005). Overall, 78 SLN samples
were collected. The average number of SLNs per patient was 3.54
(range, 1–7) and the average number of SLNs per neck side was
2.44. Neck dissections were performed for all patients, according to
the primary location for a total of 571 nodes.
SLN histopathological workup
After excision, SLNs were split and each half was embedded with
OCT, snap-frozen in pre-cooled isopentane, and stored at –801C.
Each frozen lymph node was sampled in its entirety without any
paraffin embedding. Two 5-mm-thick frozen slices were collected
every 250mm under RNase-free conditions (one slide for
haematoxylin–eosin (HE) stain and the other for pancytokeratin
IHC). For example, a 1-cm node would be sectioned 2 40 times.
The rest of the lymph node tissue was blended and sent for QRT–
PCR analysis. Immunohistochemistry used primary antibodies
anti-CKs AE1/AE3 (Novocastra Laboratories Ltd, Newcastle, UK)
and was performed using the Ventana DAB Detection Kit with the
BENCHMARK XT Ventana Medical Systems Automate (Illkirch,
France).
SLN and patient staging
Results were expressed according to Hermanek’s classification, that
is, ITCs o200mm, MI p2mm, andMA42mm (Hermanek et al,
1999). Of 78 SLN samples, 9 (11.54%) were positive for tumour, that
is, containing at least 1 MI (n¼5) or MA (n¼4). The number of
metastases per SLN was one each in five cases, and two, three, and
four in one case each. Of the 78 SLN samples, 69 were negative for
tumour, that is, containing ITC only (n¼12) or no tumoural cell
(n¼57). Patient necks were staged by taking into account the maxi-
mum size of metastases found in their SLNs. Six patients (27.3%)
were therefore staged SLNþ because of the presence of an MI or an
MA in at least one of their SLNs. A total of 16 patients (72.7%)
were staged SLN  because of the presence of ITC only (n¼6) or
because of the absence of any tumoural cells (n¼10). Isolated
tumour cells were not considered pathological, given that the clinical
relevance of such a status is unknown. In all, 11 control lymph nodes
from non-cancerous patients were analysed following the same
procedure and were similarly entered for molecular analysis.
Total RNA extraction and RT
Lymph node tissue remaining after tissue sectioning for immuno-
histochemical analysis was used for real-time RT–PCR quantifica-
tion of target mRNA. For this, total RNA was extracted from frozen
tissues using the RNeasy mini kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. RNA integrity was
Table 1 Clinicopathological characteristics of the HNSCC population
Patient
no.
Age
(years) Gender
Tumour
location cTNM
No.
SLN
SLN
location
a
Histopathology
of SLN
b
Bilateral neck
dissection
No. of non-SLN
(neck dissection)
Final pN
stage
c
12 9 M O T T 2N0M0 4 IB, IIA MI No 29 pN1
25 8 M O T T 1N0M0 3 III MA No 25 pN1
35 1 M O C T 1N0M0 7 IB, II A, III MI Yes 27 pN1
45 3 M O T T 2N0M0 5 IB, IIA, III 0 Yes 29 pN0
53 7 M O T T 2N0M0 3 IB, IIA, IV MA No 18 pN1
64 4 M O C T 2N0M0 4 IA,IB, III MA Yes 84 pN2bR+
75 5 M O C T 2N0M0 3 IB, III ITC Yes 36 pN0
84 7 F O T T 1N0M0 1 III ITC No 16 pN0
95 9 M O P T 2N0M0 2 III 0 No 21 pN0
10 61 M OC T2N0M0 3 IB, IIA 0 Yes 40 pN0
11 57 M OC T1N0M0 5 IB, IIA, III, IV 0 Yes 36 pN0
12 31 F OC T2N0M0 4 IIA, IV ITC No 17 pN0
13 66 M OT T1N0M0 3 IB, IIA, III ITC No 17 pN0
14 49 F OT T2N0M0 3 III 0 Yes 8 pN0
15 79 M OP T1N0M0 4 IIA 0 No 3 pN0
16 75 F OP T2N0M0 4 II A,III 0 No 5 pN0
17 62 M OT T2N0M0 2 III 0 No 22 pN0
18 60 F OC T1N0M0 5 IA, IB, IV 0 Yes 13 pN0
19 61 M OC T2N0M0 3 IA, III MI Yes 44 pN2b
20 59 F OP T2N0M0 2 IIA, IIB ITC No 13 pN0
21 56 F OP T1N0M0 4 II A,III 0 No 17 pN0
22 49 M OC T1N0M0 4 IB, IIA, V ITC Yes 22 pN0
Abbreviations: cTNM¼clinical tumour node-metastasis stage; FOM¼floor of mouth; HNSCC¼head and neck squamous cell carcinoma; ITC¼isolated tumour cell;
MA¼macrometastasis; MI¼micrometastasis; OP¼oropharynx; OT¼oral tongue; SLN¼sentinel lymph node; SR¼sex ratio; m¼mean; T¼total.
aCervical lymph node
levels according to Robbins et al (2002).
bPathological examination of the SLN by serial step sectioning and immunohistochemistry according to the classification of Hermanek
(6).
cpN stage was established according to the SLN and non-SLN status. The presence of isolated tumour cells was not taken into account in determining the final pN stage. No
false negative cases were noted (pN+ with negative SLN)
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sverified using a 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). For first-strand cDNA synthesis, 5mg of total
RNA, 200ng of random hexamers, and 1ml dNTP mix (10mM)
were incubated for 5min at 651C in a total volume of 13mli n
RNAse-free water. A volume of 4mlo f5  first-strand buffer, 1ml
of 1 M DTT, 40UI of RNAseOUT Recombinant Ribonuclease
Inhibitor (Invitrogen, Carlsbad, CA, USA), and 200Units of
Superscript III (Invitrogen) were then added to make a total
volume of 20ml. The mix was then incubated for 5min at 251C and
thereafter for 60min at 601C. The reaction was stopped by
incubating at 701C for 15min. Complementary DNAs were frozen
at  201C until use.
Real-time QRT–PCR analysis
Gene-specific oligonucleotide primers, amplicon length, and PCR
conditions for all primers tested are shown in Supplementary
Table 1. PCRs were performed in 20ml final volumes in capillary
tubes in a LightCycler instrument (Roche Diagnostic, Mannheim,
Germany). Reaction mixtures contained 2ml of LightCycler
FastStart DNA mastermix for SYBR Green I (Roche Diagnostic),
0.5mM of each primer, and 2ml of template DNA. All capillaries
were sealed, centrifuged at 500g for 5s, and then amplified in a
LightCycler instrument, with activation of polymerase (951C for
10min), followed by 45 cycles of 10s at 951C, 10s at the annealing
temperature, and 9s at 721C. The temperature transition rate was
201C per s for all steps. The double-stranded PCR product was
measured during the 721C extension step by detection of
fluorescence associated with the binding of SYBR Green I to the
product. Fluorescence curves were analysed using LightCycler
software version 3.5.
Data with regard to CK17, PVA,a n dSCCA were normalised
according to data obtained from three housekeeping genes, including
b2-microglobulin (b2-MG), TBP,a n dRS9. Only CK17, SCCA, and
PVA mRNA quantification results normalised with TBP mRNA
expression are presented in this paper, but similar results were found
using the other two housekeeping genes (data not shown).
Standard curves
Human b2-MG, RS9, TBP, CK17, PVA, and SCCA cDNAs were
obtained from a normal lymph node, amplified with the indicated
primers, and cloned into the pCR2.1 vector (TOPO TA Cloning Kit;
Invitrogen). Plasmids were then digested with HindIII and XbaI
restriction enzymes (Boehringer, Mannheim, Germany), extracted
from 3% agarose gel, reamplified, and purified (PCR Purification Kit;
Qiagen). The purified fragment solution was measured in a
spectrophotometer, and the molecule number was calculated. Serial
dilutions were then prepared, which ranged from 10
6 to 10
1 b2-MG,
RS9, TBP, CK17, PVA, and SCCA molecules per 100ng of cDNA in a
background of herring sperm DNA in Tris-EDTA buffer, pH 8.0.
A calibration curve was generated by analysis of plasmid
dilutions for each target. For this purpose, each calibrator was
correlated to its threshold cycle value (Ct), that is, the cycle
number when a given sample becomes positive, defined as a
measured fluorescence 410 s.d. above the background fluores-
cence. Supplementary Figure 1 shows the amplification plot of the
calibrators (Supplementary Figure 1A), the calibration curve
(Supplementary Figure 1B), and the corresponding results when
the melting curve was determined (Supplementary Figure 1C). For
each analysis, concentrations of calibrators and samples were
calculated from the calibration curve generated. The assay
quantitatively detected 10 copies per 100ng of cDNA for each
target. Each measurement was performed in triplicate and was
repeated at least twice. Thus, when the results obtained from 5 4
replicates of each calibrator and sample were considered, the intra-
assay CV was o5%, whereas the inter-assay CV was o10%, as
calculated by variation from the mean.
Statistical analysis
A comparison of the different markers between each SLN group was
carried out using a non-parametric Kruskal–Wallis test. Differences
were considered statistically significant when Po0.05. Multivariate
analysis was based on receiver-operating characteristic (ROC)
curves, which allow the characterisation of the discrimination
between two well-defined populations. Statistical analyses were
performed using STATA 10.0 software (StataCorp 2007; Release 10,
College Station, TX, USA) and mROC software (Kramar et al, 2001).
Quantitative PCR data were analysed with the unpaired Mann–
Whitney test using GraphPad InStat (version 3.06). The level of
statistical significance was set at the value of Po0.05.
RESULTS
Sensitivity of quantitative real-time RT–PCR assay
To estimate the sensitivity of QRT–PCR assays, serial dilution
experiments were carried out for CK17, SCCA, and PVA. A volume
of 100ng of cDNA derived from a cDNA pool of three histologically
positive SLNs was diluted from 10
1 to 10
6 and subjected to QRT–
PCR assay. In Supplementary Figure 1A, amplification plots for the
sample containing serial dilutions of cDNA derived from this pool
are overlaid. Standard curves were constructed from plots for the
calculated Ct values of each reaction. Threshold values obtained
with the standard dilution series revealed quantification of CK17,
SCCA, and PVA total RNA, with a linear range (r40.99) from 10
1
to 10
6 copies per 100ng cDNA in repeated experiments (Supple-
mentary Figures 1A and B). All assays of a pool of positive SLN
cDNAs ailed to generate results because of amplification of the
processed pseudogenes, as observed with the melting curves
(Supplementary Figure 1C). Three housekeeping genes, RS9, TBP,
and b2-MG, were quantified as internal standards and similar
results were obtained (data not shown).
Correlation of SLN quantitative CK17, SCCA, and PVA
mRNA expressions and histopathological findings
Among the 89 lymph nodes (78 SLNs and 11 control nodes), 88
(98.8%), 64 (72.7%), and 27 (30.3%) showed CK17 (3.1 10
5 –7
copies per 100ng cDNA), SCCA (9.4 10
4 – 2 copies per 100ng
cDNA), and PVA (6.4 10
4 – 3 copies per 100ng cDNA) mRNA
expressions, respectively. In all, 3 of 4 MA and 0 of 5 MI SNLs
expressed CK17/TBP mRNA values that were higher than the
maximum value obtained for ITC (n¼12) and the negative control
(n¼57). All MA SLN samples expressed higher SCCA/TBP mRNA
values compared with those obtained from other groups. Interest-
ingly, PVA/TBP mRNA values were higher for both MA and MI
SNLs, including two MI SLNs sized o450mm, compared with the
maximum mRNA value obtained for the negative-SLN group. To
exclude false negatives, optimal threshold values were calculated
to maximise sensitivity to 100% (CK17¼236.6; SSC¼9.9;
PVA¼179.8). Values above or equal to these ‘cutoff’ values were
defined as QRT–PCR positive. The results of the comparison
between histological examination and the absolute QRT–PCR
method using a ‘cutoff’ value are shown in Table 2. No significant
difference was found in the mRNA levels measured with QRT–PCR
between the negative group (SLN without metastasis) and a group of
11 control LNs (non-cancerous patients) for CK17, SCCA, and PVA
(P40.05) (data not shown). The MA SLN group showed mean
expression levels of CK17 that were higher than those of the negative
control node group (negative node and ITC) (Po0.01), whereas MI
SLNs expressed CK17 mRNA levels that were not significantly
different from those of the negative control node group (Figure 1).
Similar results were obtained for SCCA, with a significant difference
observed only between the MA group and the negative node group
(Po0.01) (Figure 1). However, interestingly, PVA showed a higher
QRT–PCR for sentinel node staging in head and neck cancer
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smRNA expression in the MA and MI SLN groups than in the
negative control node group, with significant differences not only
between MA (Po0.001) but also between MI SLN and controls
(Po0.001) (Figure 1). None of the three tested markers allowed the
ITC group to be distinguished from negative controls (P40.05).
Correlation of patient staging with quantitative CK17,
SCCA, and PVA mRNA expression
The CK17/TBP, SCCA/TBP, and PVA/TBP mRNA values were next
used to analyse data according to patient status as determined by
serial sections and IHC analyses (Table 2). A significant difference
in mRNA levels in patients with metastasis-positive SLNs
compared with metastasis-negative SLNs was found for CK17
(Po0.005), SCCA (Po0.0001), and PVA (Po0.0001). Receiver-
operating curve analyses showed an area under the curve of 93.8%
(95% CI (83.7–100)) for CK17, 97.9% (95% CI (92.8–100)) for
SCCA, and 100.0% for PVA (Figure 2). Receiver-operating curve
analyses for CK17 allowed the determination of a ‘cutoff’ value of
1436 with 81.2% specificity (95% CI (54.3–95.9)), 100% sensitivity
(95% CI (54.1–100)), and 86.3% accuracy. For SCCA, a ‘cutoff’
value of 48 was calculated, with a specificity of 93.7 (95% CI (69.8–
99.8)), a sensitivity of 100% (95% CI (54.1–100)), and an accuracy
of 95.4. For PVA, 100% specificity (95% CI (79.4–100)), sensitivity
(95% CI (54.1–100)), and accuracy were obtained with a ‘cutoff’
value of 562 (Figure 3). For an SLN invasion prevalence of 27.3%,
the positive predictive values of CK17, SCCA, and PVA were 79.3,
91.2, and 100%, respectively.
DISCUSSION
At present, the missing link in the SLN strategy, particularly in
HNSSC, seems to hinge on the accuracy of the intra-operative
diagnosis of neck involvement. The SLN is defined as the first
element that receives lymphatic drainage from an anatomical area
harbouring a primary malignant tumour. Overall, 95% of cancer
cells metastasise to SLNs (Zurrida et al, 2001). Sentinel lymph nodes
are easily identified by injecting radioisotope or blue dye around the
primary tumour. However, an important issue that needs to be
solved in establishing the method is the diagnostic accuracy of MI.
The worldwide ‘gold standard’ is HE staining. Lymph nodes are
usually diagnosed as either metastatic or non-metastatic by
examining one or two sections of the maximal cut surface. However,
as the median size of the metastatic tissue to be diagnosed is
B350mm, the sensitivity of routine frozen sectioning is only 20%
(Atula et al, 2009). Semi-serial sectioning, associated with IHC, has a
higher detection rate of MI than examination of only a few sections,
and can reach the sensitivity of intra-operative fine-sectioned frozen
sectioning of 93% (Tschopp et al, 2005). However, this approach is
very time consuming and the inevitable loss of material can lead to
some MIs being missed (van Diest et al, 2001). Furthermore, as the
results reported are partly due to a high degree of attention and skill
being provided by pathologists during clinical studies, such results
are not likely to be achievable in a routine clinical setting (van Diest
et al, 2001). Molecular diagnosis with QRT–PCR may be a
substitute for histopathology for intra-operative SN analysis. Indeed,
this rapid technique seems to be a valuable tool for the detection of
lymph node invasion of breast adenocarcinomas (Kataoka et al,
2000), skin melanomas (Blaheta et al, 2001), and HNSCC
(Hamakawa et al, 2000, 2004; Becker et al, 2004; Shores et al,
2004). We have previously shown that CK17 mRNA quantification
could accurately determine sentinel node staging (Garrel et al,
2006). However, this marker did not permit the detection of MIs
sized o450mm. As all undiagnosed MIs were associated with larger
MIs or MAs, exact neck staging was finally achieved. Therefore, as
the CK17 mRNA ‘cutoff’ value separating positive and negative
nodes overlapped, more robust tumour-related markers clearly need
to be validated. Recently, Ferris et al (2005) screened 40 potential
markers using primary tumour and gross metastatic deposits and
compared these with benign nodes. Among the screened markers,
SCCA and PVA mRNA quantification provided a remarkable
discrimination between positive and benign lymph nodes, and were
thus proposed as potentially relevant markers for the staging of
cervical lymph nodes in HNSCC. Despite this encouraging work, no
studies have thus far addressed the possibility of intra-operative
SCCA and PVA QRT–PCR analysis of SLNs in patients with
HNSCC. We addressed this issue in this report and determined the
diagnostic accuracy of the molecular diagnosis.
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Figure 1 Absolute RT–PCR quantification of CK17, SCCA, and PVA
mRNA in 78 SLNs. SLN status is determined according to histological
status. mRNA quantification is expressed relative to the TBP housekeeping
gene. Horizontal line, median. ITC, isolated tumour cell; MI, micrometas-
tasis, MA, macrometastasis.
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sIt is clear that real-time evaluation allows the detection of a
signal at the earliest stage of metastasis, providing a more accurate
indication of small tumour deposit than older RT–PCR methods
that measure only at a defined end point. In this study, we first
developed highly sensitive and quantitative assays for CK17, SCCA,
and PVA RT–PCR assays (Supplementary Figure 1). We designed
our original primers to minimise amplification of illegitimate
mRNA. The expression level of each marker gene was calculated
relative to the standard curve and corrected for the input of cDNA
on the basis of the control housekeeping gene. Standard curves
were generated from a pool of positive SLNs to ensure that every
marker gene tested is expressed at high levels, thereby creating
reproducible and reliable experiments. The results showed that
very low levels of the marker-related gene (until 10
1 copies per
100ng cDNA for the three target genes, with rX0.98) could be
detected. Second, we determined the reliability of real-time RT–
PCR in comparison with histopathology data on 78 SLNs obtained
from 22 HNSCC patients and 11 SLNs from non-cancerous
patients. All MA SLNs were identified with SCCA and PVA mRNA
quantification, whereas one of the four MA SLNs was not detected
by real-time QRT–PCR of CK17 mRNA. In this latter case, the
corresponding SLN was deemed positive by HE staining and IHC.
In addition, PVA was the only marker that significantly
distinguished small amounts of neoplastic tissue, that is, MI from
negative nodes, including lesions o450mm. Interestingly, the
background level and dispersion of mRNA values were very low
for this marker (Figure 1). The QRT–PCR method was therefore
used to establish a ‘cutoff’ value to maximise the sensitivity of the
test (100%). Specificity increased progressively between CK17 and
SCCA and reached 100% for SLN staging by PVA mRNA
quantification (Table 2). With QRT–PCR, no false-negative case
for PVA was observed in either SLNþ or SLN  patients, whereas
one and three patients were misclassified with SCCA and CK17,
respectively(Figure 3). Finally, mRNA quantification of SCCA and
PVA allowed 95.4 and 100% accuracy, respectively. This important
finding is in agreement with the study by Ferris et al (2005), which
reported a test accuracy of 100 and 99.1%, respectively. By
providing this 100% discrimination between positive and negative
SLNs, PVA could be proposed as an adequate marker for the
QRT–PCR diagnosis of minute SLN invasion of HNSCC.
With regard to the issue of ITCs, there is growing evidence that
in head and neck cancer, ITC could be associated with a worse
prognosis compared with pN0 SLN, a finding that contrasts with
that which is observed in breast adenocarcinoma (Atula et al,
2009). Consequently, we assessed the ability of PVA mRNA
quantification to diagnose ITC by varying the PVA cutoff point.
Selecting a lower cutoff value of 22.68, only two patients with ITC
were reclassified as ‘node-positive’, whereas four patients remained
‘node-negative’. Moreover, with this cutoff value, the specificity and
sensibility rates of the test were 100 and 66.67%, respectively.
Therefore, from these results, we concluded that, in our study, PVA
is unable to distinguish ITC from ‘node-negative’ patients. The
absence of any correlation between mRNA quantification and the
presence of ITC can probably be explained by the histopathological
workup of the lymph nodes used. The reference test, that is, serial
sections every 250mm with IHC, is clearly not accurate enough to
diagnose all cases of ITC, leading to some false-negative cases in the
pN0 group. However, irrespective of the reason for these findings, a
more focused study on ITC with a deeper histopathological workup
and a more accurate quantification of minute tumours in SLN is
highlighted as a useful area for future research.
With regard to markers, SCCA is a member of the ovalbumin
family of serine proteinase inhibitors. The SCCA protein is
expressed in neutral and acidic forms, designated as SCCA
(SERPINB3) and SCCA2 (SEPINB4). Both genes locate at 18q21.3
very closely, generating a cluster of serpins, together with
plasminogen activator inhibitor type 2 and maspin, suggesting
that either the SERPINB3 or the SEPINB4 gene could arise from the
other by gene duplication (Schneider et al, 1995). For SCCA
amplification by RT–PCR, we designed primers that could detect
both mRNA isoforms. Squamous cell carcinoma antigen-1 was
originally purified from squamous cell carcinoma of the uterine
cervix (Kato and Torigoe, 1977), and subsequently it turned out
that SCCA1 and SCCA2 were co-expressed broadly in the
superficial and intermediate layers of normal squamous epithe-
lium. The biological functions of SSCA still remain obscure,
Table 2 RT–PCR marker analysis according to lymph node staging (n¼78) or patient staging (n¼22)
SLN histological staging Patient staging
Negative node (n¼57) ITC (n¼12) MI (n¼5) MA (n¼4) SLN  (n¼16) SLN+ (n¼6)
CK17
Negative 9 (15.8%) 2 (16.6%) 0 (0%) 0 (0%) 13 (81%) 0 (0%)
Positive 48 (84.2%) 10 (83.3%) 5 (100%) 4 (100%) 3 (19%) 6 (100%)
SSCA
Negative 36 (63.1%) 6 (50%) 0 (0%) 0 (0%) 15 (94%) 0 (0%)
Positive 21 (36.8%) 6 (50%) 5 (100%) 4 (100%) 1 (6%) 6 (100%)
PVA
Negative 57/57 (100%) 12/12 (100%) 0 (0%) 0 (0%) 16 (100%) 0 (0%)
Positive 0 (0%) 0 (0%) 5 (100%) 4 (100%) 0 (0%) 6 (100%)
Abbreviations: CK17¼cytokeratin 17; ITC¼isolated tumour cell; MA¼macrometastasis; MI¼micrometastasis; RT–PCR¼reverse transcriptase-PCR; SLN¼sentinel lymph
node; PVA¼Pemphigus vulgaris antigen; SSCA¼Squamous cell carcinoma antigen.
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Figure 2 Receiver-operating characteristic curves for CK17, SCCA, and
PVA. The AUC for PVA was 100%.
QRT–PCR for sentinel node staging in head and neck cancer
J Solassol et al
185
British Journal of Cancer (2010) 102(1), 181–187 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
salthough it has been reported that these proteins confer resistance
against tumour necrosis factor-a- or radiation-inducing apoptosis
(Suminami et al, 2000; Murakami et al, 2001). Finally, the
expression of SCCA2 in cancer has been associated with an
aggressive phenotype, and this gene has been used in several
studies for the detection of squamous cell carcinoma metastases to
lymph nodes (Kano et al, 2000). Pemphigus vulgaris antigen (also
known as desmoglein 3 – DSG3) is one of the components of
desmosome. Desmosomes are button-like points of intercellular
contact that couple cytoskeletal elements to the plasma membrane
at cell-to-cell or cell-to-substrate adhesions. A disorder related to
DSG3 is pemphigus vulgaris (Amagai et al, 1991), an autoimmune
disease associated with the production of autoantibodies against
PVA responsible for the loss of cell-to-cell adhesion. Reports with
regard to the clinical association of PVA expression with HNSCC
cancer are few and seem inconsistent. Recently, Chung et al (2004)
determined gene expression patterns from 60 HNSCC samples
assayed on cDNA microarrays that allowed categorisation of these
tumours with the clinical outcome of patients. Among the genes
involved in the prognostic profile, PVA was found to be
overexpressed in invasive cancer associated with a high metastatic
potential. This result was confirmed more recently in a similar
profiling approach (Chen et al, 2007). In our study, we observed
that PVA was significantly expressed in SLNþ samples relative
to SLN  samples. No cases with positive QRT–PCR and negative
histopathology were observed. However, to avoid any such
problem, careful dissection of the lymph node must be carried
out so as to remove any contaminating non-lymphatic tissue.
Finally, the morphological analysis of SS-IHC remains the
gold standard for definitive histopathology to correct any
erroneous diagnoses in cases of QRT–PCR inaccuracy and
to search for histo-prognosis factors, such as capsular lymph
node invasion. Therefore, if QRT–PCR analysis of SLNs is
to be used in clinical practice, it should be included in
multimodality diagnostic protocols similar to the one reported in
this study.
We are aware that further investigations in larger cohorts are
required to validate QRT–PCR of PVA mRNA and to establish
inter-laboratory variations for an efficient detection, with high
sensitivity and specificity, of metastatic disease in SLNs of patients
with HNSCC. However, our findings have potentially important
implications for the prospective assessment of molecular
methodologies. We have provided additional data that could lead
to better management of HNSCC patients by reducing the rate of
false-negative SLNs using a QRT–PCR approach with quantifica-
tion of PVA mRNA levels. On the basis of the present results,
future studies assessing either an automated technique for mRNA
quantification of PVA with QRT–PCR or using one-step nucleic
acid amplification (Tsujimoto et al, 2007) may pave the way
towards achieving worthwhile intra-operative molecular staging of
SLNs in HNSCCs.
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